DNAJC12 As a Mediator Between ESR1 and ERBB4 in Breast Carcinoma Cells

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 15

PMID 33718139

Authors

Mianjie Lin

Ya-Nan Wang

Yixin Ye

Zhelei Xiong

Fengbiao Guo

Haibin Chen

Affiliations

Soon will be listed here.

Abstract

Mutation of the DNAJC12 gene is typically associated with non-progressive Parkinsonism, but is also detectable in breast carcinoma where its contribution and mechanisms are unexplored. In breast carcinoma, ESR1 was positively correlated with DNAJC12 and ERBB4, and DNAJC12 was positively correlated with ERBB4. We used the GEO2R tool to compare differential gene expression of MCF-7 cells, following ESR1 knockdown (GEO database, E-GEOD-27473 array), and found decreased expression of DNAJC12 and ERBB4 in ESR1-silenced MCF-7 cells. The number of identical genes having correlativity with ESR1, DNAJC12, or ERBB4 was 12,165 (66.41%). These results suggest that ESR1 can promote the expression of DNAJC12 and ERBB4, and DNAJC12 can enhance the expression of ERBB4 in MCF-7 cells, implying that there may be a regulatory network among these three genes.

Citing Articles

Downregulation of DNAJC12 Expression Predicts Worse Survival for ER-Positive Breast Cancer Patients.

Gatti P, Mangone F, Pavanelli A, Nonogaki S, Osorio C, Capelozzi V Biomark Insights. 2025; 20:11772719251323095.

PMID: 40008192 PMC: 11851741. DOI: 10.1177/11772719251323095.

References

Uno Y, Kanda M, Miwa T, Umeda S, Tanaka H, Tanaka C . Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer. Ann Surg Oncol. 2019; 26(3):836-844. DOI: 10.1245/s10434-018-07149-y. View

Kang B, Plescia J, Song H, Meli M, Colombo G, Beebe K . Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest. 2009; 119(3):454-64. PMC: 2648691. DOI: 10.1172/JCI37613. View

Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, Elenius K . Function of ERBB4 is determined by alternative splicing. Cell Cycle. 2011; 10(16):2647-57. DOI: 10.4161/cc.10.16.17194. View

Farre D, Roset R, Huerta M, Adsuara J, Rosello L, Alba M . Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003; 31(13):3651-3. PMC: 169011. DOI: 10.1093/nar/gkg605. View

Zhu J, Xiong G, Fu H, Evers B, Zhou B, Xu R . Chaperone Hsp47 Drives Malignant Growth and Invasion by Modulating an ECM Gene Network. Cancer Res. 2015; 75(8):1580-91. PMC: 4401637. DOI: 10.1158/0008-5472.CAN-14-1027. View

Wang X, Chen M, Zhou J, Zhang X . HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review). Int J Oncol. 2014; 45(1):18-30. DOI: 10.3892/ijo.2014.2399. View

Yang Z, Zhang Q, Yu L, Zhu J, Cao Y, Gao X . The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer. J Ethnopharmacol. 2020; 264:113249. DOI: 10.1016/j.jep.2020.113249. View

Sharma A, Upadhyay A, Bhat M . Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells. Cancer Biol Ther. 2009; 8(22):2106-13. DOI: 10.4161/cbt.8.22.9687. View

Xiong X, Wang Y, Liu C, Lu Q, Liu T, Chen G . Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells. Exp Cell Res. 2014; 326(1):78-89. PMC: 4120946. DOI: 10.1016/j.yexcr.2014.05.018. View

10.

Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M . Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999; 10(1):47-52. DOI: 10.1023/a:1008337009350. View

11.

Bubnov V, Moskalev E, Petrovskiy Y, Bauer A, Hoheisel J, Zaporozhan V . Hypermethylation of TUSC5 genes in breast cancer tissue. Exp Oncol. 2013; 34(4):370-2. View

12.

Yang Y, Xing Y, Liang C, Hu L, Xu F, Chen Y . Crucial microRNAs and genes of human primary breast cancer explored by microRNA-mRNA integrated analysis. Tumour Biol. 2015; 36(7):5571-9. DOI: 10.1007/s13277-015-3227-3. View

13.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

14.

Ghoncheh M, Pournamdar Z, Salehiniya H . Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev. 2016; 17(S3):43-6. DOI: 10.7314/apjcp.2016.17.s3.43. View

15.

Bagheri F, Mesrian Tanha H, Naeini M, Ghaedi K, Azadeh M . Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3'-untranslated region of ErbB4 in breast cancer. Mol Med Rep. 2016; 13(5):4494-8. DOI: 10.3892/mmr.2016.5078. View

16.

Kurozumi S, Yamaguchi Y, Matsumoto H, Kurosumi M, Hayashi S, Fujii T . Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy. PLoS One. 2019; 14(5):e0217279. PMC: 6528995. DOI: 10.1371/journal.pone.0217279. View

17.

Jia Y, Song Y, Dong G, Hao C, Zhao W, Li S . Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer. Sci Rep. 2019; 9(1):12939. PMC: 6736845. DOI: 10.1038/s41598-019-49373-w. View

18.

Green M . In-vitro antimicrobial susceptibility of Neisseria gonorrhoeae in New Zealand. Br J Vener Dis. 1978; 54(5):316-21. PMC: 1045530. DOI: 10.1136/sti.54.5.316. View

19.

Gibert B, Hadchity E, Czekalla A, Aloy M, Colas P, Rodriguez-Lafrasse C . Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene. 2011; 30(34):3672-81. DOI: 10.1038/onc.2011.73. View

20.

Yamamoto H, Higa-Nakamine S, Noguchi N, Maeda N, Kondo Y, Toku S . Desensitization by different strategies of epidermal growth factor receptor and ErbB4. J Pharmacol Sci. 2014; 124(3):287-93. DOI: 10.1254/jphs.13r11cp. View